Literature DB >> 3620285

The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

J Posner, M Danhof, M W Teunissen, D D Breimer, P D Whiteman.   

Abstract

1 Oxidative metabolism of antipyrine (AP) was compared in 11 elderly (greater than 65 years) and 12 young (less than 40 years) volunteers. All subjects were non-smokers, consumed little if any alcohol and were in good health. 2 After a single dose of AP 500 mg, its clearance from saliva and profiles of the parent drug and its major metabolites in urine were determined using high-performance liquid chromatography. 3 Mean total AP clearance from saliva was lower in the elderly (P less than 0.05). Mean weight-normalised volume of distribution was also smaller (P less than 0.01) so that elimination half-life in the elderly was not significantly different from that in the young. 4 The percentage dose excreted in 48 h urine as norantipyrine (NORA) and its clearance for production were lower in the elderly (P less than 0.001 and P less than 0.01 respectively). Urinary 3-hydroxymethylantipyrine (HMA) and free antipyrine were present in greater quantities in 48 h urine in the elderly (P less than 0.001 and P less than 0.05) while the amounts of 4-hydroxyantipyrine (OHA) were almost identical in the two age groups. 5 The findings suggest that there is a selective impairment of N-demethylation in the elderly which may have important implications for dosage of elderly patients with drugs metabolised by this route.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3620285      PMCID: PMC1386279          DOI: 10.1111/j.1365-2125.1987.tb03135.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Pharmacokinetics in the aged: a review.

Authors:  E J Triggs; R L Nation
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

2.  Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking.

Authors:  R E Vestal; A H Norris; J D Tobin; B H Cohen; N W Shock; R Andres
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

3.  Hepatic drug acetylation and oxidation: effects of aging in man.

Authors:  F Farah; W Taylor; M D Rawlins; O James
Journal:  Br Med J       Date:  1977-07-16

4.  Assessment of antipyrine kinetics by measurement in saliva.

Authors:  H S Fraser; J C Mucklow; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

5.  Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.

Authors:  C J van Boxtel; J T Wilson; S Lindgren; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

Review 6.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

7.  Vocational training for general practice: a preliminary report.

Authors:  J H Walker; A Smith; D Irvine
Journal:  Br Med J       Date:  1971-01-02

8.  Lorazepam kinetics in the elderly.

Authors:  D J Greenblatt; M D Allen; A Locniskar; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

Review 9.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.

Authors:  M W Teunissen; P Spoelstra; C W Koch; B Weeda; W van Duyn; A R Janssens; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

View more
  6 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

3.  The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.

Authors:  H Sakai; S Kobayashi; K Hamada; S Iida; H Akita; E Tanaka; E Uchida; H Yasuhara
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin.

Authors:  N M Waite; M J Rybak; D J Krakovsky; J D Steinberg; L H Warbasse; D J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

Review 5.  Age-related changes in hepatic function. Implications for drug therapy.

Authors:  K Woodhouse; H A Wynne
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

6.  Age-related changes in the hepatic pharmacology and toxicology of paracetamol.

Authors:  Sarah J Mitchell; Alice E Kane; Sarah N Hilmer
Journal:  Curr Gerontol Geriatr Res       Date:  2011-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.